Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版

Ahead of print
Authors' Accepted
Current Issue
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us

Resources & Services

Email alert

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the

AJA Club (in English)
AJA Club (in Chinese)


Volume 11, Issue 1 (January 2009) 11, 14–21; 10.1038/aja.2008.20

Molecular markers in prostate cancer. Part I: predicting lethality

Sachin Agrawal and William D. Dunsmuir

Department of Urology, St. Peters Hospital, Chertsey KT160PZ, UK

Correspondence: Mr Sachin Agrawal, Department of Urology, St. Peters Hospital, Chertsey KT16 0PZ, UK. Tel: +44-19-3272-2640 E-mail: agrawalsachin@hotmail.com

Received 29 September 2008; Accepted 2 October 2008; Published online 1 December 2008


Assessing the lethality of 'early,' potentially organ-confined prostate cancer (PCa) is one of the central controversies in modern-day urological clinical practice. Such cases are often considered for radical 'curative' treatment, although active surveillance may be equally appropriate for many men. Moreover, the balance between judicious intervention and overtreatment can be difficult to judge. The patient's age, comorbidities, family history and philosophy of self-health care can be weighed against clinical features such as the palpability of disease, the number and percentage of biopsy cores involved with the disease, histological grade, presenting prostate-specific antigen (PSA) and possible previous PSA kinetics. For many years, scientists and physicians have sought additional molecular factors that may be predictive for disease stage, progression and lethality. Usually, claims for a 'new' unique marker fall short of true clinical value. More often than not, such molecular markers are useful only in multivariate models. This review summarizes relevant molecular markers and models reported up to and including 2008.

Keywords: genetics, neoplasm metastasis, prostate cancer

PDF | PDF | 中文摘要 |

Browse:  3902
Copyright 1999-2017  Shanghai Materia Medica, Shanghai Jiao Tong University.  All rights reserved